Table 5.
References | Study design | Subjects (n) | Age, years (mean ± SD) | Disease/symptom | Kampo formulation | Comparator | Outcome | Adverse reaction |
---|---|---|---|---|---|---|---|---|
Nakae et al. (101) | RCT | 162 | 60(16–90) 66(23–90) | Rib fracture | JDI | NSAIDs | Shorten the duration, Lower healthcare expenditure | No adverse reaction in JDI, gastrointestinal symptoms in 2.5% of the NSAIDs group |
Majima et al. (104) | RCT | 47 | 68.3 ± 10.0 71.5 ± 6.0 | Osterarthritis of knee | BOT | Loxoprofen | Improve the Knee Society Rating System and SF-36 | Dry month in a patient |
Watanabe et al. (114) | RCT | 116 | 59.4 ± 7.8 60.9 ± 7.4 | Diabetes mellitus type 2 | GJG | No GJG | Decrease progression neuropathy | None |
JDI, jidabokuippo; BOT, boiogito; GJG, goshajinkigan; NSAIDs, non-steroidal anti-inflammatory drugs; SD, standard deviaton.